Use of statins in children;Uso de estatinas durante la infancia

Anales de Pediatria

Volumn 68, Issue 4, 2008, Pages 385-392

  Tapia Ceballos, L ^a   Picazo Angelin B ^a   Ruiz Garcia C ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Atherosclerosis; Hypercholesterolemia; Hyperlipidemia; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; DYSPEPSIA; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; METEORISM; MIGRAINE; MYALGIA; PRURITUS; RASH; REVIEW; SIDE EFFECT;

EID: 42149116897     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13117712     Document Type: Article

References (42)

1. Durrington P. Dyslipidaemia. Lancet. 2003;362:717-31.
2. McCrindle BW. Hyperlipidemia in children. Thrombosis research. 2006;118:49-58.
3. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:55-68.
4. Abidafel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6.
5. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidake H, Kojima H, et al. Two genes that map to STSL locus cause sitosterolemia: Genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet. 2001;69:278-90.
6. Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, et al. Autosomal recessive hypercholesterolemia in Sardinia, Italy, and mutations in ARH: A clinical and molecular genetic analysis. Lancet. 2002;359:841-7.
7. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, et al. Human cholesterol 7 alpha hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110:109-17.
8. Tapia Ceballos L. Síndrome metabólico en la infancia. An Pediatr (Barc). 2007;66:159-66.
9. De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG. Family history of cardiovascular events and endothelial dysfunction in children with hypercholesterolemia. Atherosclerosis. 2002;163:193-7.
10. Wiegman A, De Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet. 2004;363:369-70.
11. Relationship of atherosclerosis in young men to serum lipoprotein colesterol concentrations and smoking: A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018-24.
12. Newman WP III, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerotisis: The Bogalusa Heart Study. N Engl J Med. 1986;314:138-44.
13. Li S, Chen W, Srinivasav SR, Bond MG, Tang R, Urbina EM, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa Heart Study. JAMA. 2003;290:2271-6.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assesment of endothelial flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-65.
15. De Jongh S, Lilien MR, Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117-21.
16. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:525-84.
17. Tammi A, Ronnemaa T, Gylling H, Rask-Nissila L, Viikari J, Tuominen J, et al. Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy children: The STRIP project: Special Turku Coronary Risk Factors Intervention Projet. J Pediatr. 2000;136:503-10.
18. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripuberal and prepuberal children with familial hypercholesterolemia. J Pediatr. 1996;129:42-9.
19. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductasa. Science. 2001;292:1160.
20. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
21. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41.
22. Rodenburg J, Visser MN, Trip MD, Wiegman A, Bakker HD, Kastelein JJP. The spectrum of statin therapy in hyperlipidemic children. Seminars in Vascular Medicine. 2004;4:313-20.
23. De Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231-7.
24. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolemia: A randomized controlled trial. JAMA. 2004;292:331-7.
25. Ducobu J, Brasseur D, Chaudron JM, Deslypere JP, Harvengt C, Muls E, et al. Simvastatin use in children. Lancet. 1992;339:1488.
26. Couture P, Brun LD, Szots F, Lelievre M, Gaudet D, Depres JP, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1998;18:1007-12.
27. Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp Clin Res. 1999;25:23-8.
28. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescents males with heterozygous familial hypercholesterolemia: A randomized controlled trial. JAMA. 1999;281:137-44.
29. Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlosi S, et al. Treatment of familial hypercholesterolemia in children and adolescents: Effects of lovastatin: Canadian Lovastatin in Children Study Group. Pediatrics. 1996;97:619-28.
30. Claus SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Efficacy and safety of lovastatin terapy in adolescents girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116:682-8.
31. Knipscheer HC, Boelen CC, Kastelein JJP, Van Diermen DE, Groenemeijer BE, Van de Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39:867-71.
32. Wiegman A, Hutten BA, De Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA. 2004;292:331-7.
33. Hedman M, Matikainen T, Fohr A, Lappi M, Piippo S, Nuutinen M, et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: A prospective clinical follow-up study. J Clin Endocrinol Metab. 2005;90:1942-52.
34. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;142:74-80.
35. Athyros VG, Papageorgiou AA, Kontopoulus AG. Long-term treatment with atorvastatin in adolescents males with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:205-6.
36. Firth JC, Marais AD, Byrnes P, Fusco RA, Bonnici F. Fluvastatin in heterozygous familial hypercholesterolemia. Cardiol Young. 2000;10 Suppl 2:35. Abstract.
37. Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris, Pears J, et al. Safety of rosuvastatin. Am J Cardiol. 2004;94:882-8.
38. Arambepola C, Farmer AJ, Perera R, Neil HAW. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. Atherosclerosis. 2006. Nov 9.
39. Gagne C, Gaudet D, Bruckert E, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-75.
40. Lin S, Olsson AG, Eriksson M, Rudling M, Eggertsen G, Angelin B. Autosomal recessive hypercholesterolemia: Normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med. 2004;256:406-12.
41. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: Clinical evidence for "pleitropic" functions of statin therapy. Eur Heart J. 2006;27:1182-90.
42. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy oh high-risk lipid abnormalities in children and adolescents. A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-67.